As the market demand for GLP-1 weight loss drugs, represented by Wegovy, grows rapidly, not only pharmaceutical companies stand to benefit, but other players along the healthcare service chain are also poised to share in this growth dividend. As a leading U.S. pharmacy chain, CVS Health (CVS) recently launched a specialized service plan for GLP-1 drugs, drawing attention from Wall Street, with some analysts suggesting that this move enhances the stock’s investment appeal.
Through its GLP-1 dedicated service plan, CVS Health integrates more than 9,000 pharmacies across the United States into an efficient distribution network for weight loss medications, directly addressing core barriers patients face in accessing these drugs. The plan is expected not only to boost retail pharmacy revenues but also to demonstrate the synergistic advantages of the company’s diversified business model. Against a backdrop of continued performance improvement and upwardly revised outlooks, combined with a solid dividend yield, CVS Health presents itself as an attractive option for long-term investors.
Weight loss drugs have long faced multiple obstacles in patient access. The first issue is price; even with recent price reductions, GLP-1 medications can still cost several hundred dollars per month, representing a significant financial burden for many patients. At the same time, insurance coverage for weight loss therapies remains inadequate, forcing many patients in need of treatment to forgo medication. In addition, due to insurance coverage issues and other factors, some physicians are also cautious when prescribing GLP-1 drugs. Even when patients begin treatment, a considerable proportion experience uncomfortable side effects, adding further difficulty to the weight loss process.
In response to the above pain points, CVS Health announced the launch of a GLP-1 dedicated service plan across more than 9,000 pharmacies nationwide. The plan offers virtual consultation services priced at USD 49, during which clinicians evaluate patients and prescribe GLP-1 medications. In terms of drug pricing, patients with insurance coverage can pay as little as USD 25 per month, eligible Medicare patients USD 50 per month, and uninsured patients starting at USD 149 per month. In addition, CVS Health will provide one-on-one professional guidance and supply over-the-counter products to help patients manage side effects.
This initiative is expected to attract a large number of patients to CVS Health’s platform and drive revenue growth in its retail pharmacy division. Bank of America analyst Allen Lutz recently raised his price target for the stock from USD 100 to USD 110. CVS Health currently trades around USD 104, implying upside potential from current levels based on the new target.
Over the past 18 months, CVS Health has performed well after several years of challenges. The company has made significant progress in controlling costs in its Medicare Advantage segment, which had previously seen rising expenses erode profits and margins. In the first quarter, CVS Health reported a 6% year-over-year revenue increase to USD 100.4 billion, with adjusted earnings per share rising 14% to USD 2.57. The company also raised its full-year fiscal 2026 guidance.
CVS Health also offers a robust dividend profile, with a current forward dividend yield of 2.5%, above the S&P 500 average of 1.1%. Over the past decade, the company has increased its dividend by 56.5%.
